Latest Reports

  • China Pharmaceuticals and Healthcare Report Q4 2016

    Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

    BMI View: China will become a leading medical research hub within the Asia Pacific region. This will be largely led by multinational pharmaceutical firms as they seek to tap the large talent pool within the country and develop treatments ‘in China, for China’. The local industry, while still largely focused on generic drugs, has started to shift towards developing innovative treatments.... 
  • Botswana Pharmaceuticals and Healthcare Report Q4 2016

    Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

    BMI View: Multinational drugmaker presence in Botswana will be limited to imports as the small market size and lack of investment incentives deter any large-scale investment plans. Although generic drugs will retain their dominance in terms of market share, as the burden of non-communicable diseases increases this will create more lucrative opportunities for foreign drugmakers. The government will... 
  • Zambia Pharmaceuticals and Healthcare Report Q3 2016

    Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

    BMI View: The Zambian government will continue to boost social expenditure as President Lungu attempts to gain public favour in light of the August general elections. Fiscal revenues will increase gradually, in line with the copper sector’s slow recovery, but real GDP growth in Zambia will still remain subdued in 2016. Government expenditure maintains a focus on unproductive areas of the economy,... 
  • Vietnam Pharmaceuticals and Healthcare Report Q3 2016

    Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

    BMI View: Leveraging Vietnam’s National Expanded Immunisation Programme (EPI) will be of strategic benefit to multinational pharmaceutical firms with a strong vaccines portfolio. Government support for the initiative is expected to remain strong, which bodes well for firms as the EPI alleviates financial barriers that might dissuade patients from receiving treatment. A key risk to this approach...